23-BRE-56-AZ (D8531C00002): A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients With ER+/HER2- Early Breast Can

Pharmacology, Toxicology and Pharmaceutical Science

1. Aromatase Inhibitor 100%
2. Tamoxifen 100%
3. Tolerability 100%
4. Endocrine Therapy 100%
5. Symptom 100%
6. Malignant Neoplasm 50%
7. Biological Marker 50%
8. Survival 50%
9. Drug 50%
10. Breast Cancer 50%
11. DNA 50%
12. Health Status 50%
13. Neoplasm 50%